B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

ADRA1D

MOLECULAR TARGET

adrenoceptor alpha 1D

UniProt: P25100NCBI Gene: 14640 compounds

ADRA1D (adrenoceptor alpha 1D) is targeted by 40 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting ADRA1D

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Phentolamine3.7642
2Yohimbine3.1823
3Tamsulosin3.1422
4Norepinephrine Precursor of epinephrine that is secreted by3.0921
5Idazoxan2.9418
6Clonidine2.5612
7Oxymetazoline2.4811
8Epinephrine2.309
9Mianserin2.208
10Buspirone2.208
11Piperoxan2.208
12Indoramin1.956
13Phenylephrine1.795
14Fluoxetine1.614
15Quetiapine Fumarate1.614
16Aripiprazole1.614
17Naphazoline1.614
18Dihydroergotamine1.393
19Methoxamine1.393
20Tolazoline1.393
21Carvedilol1.102
22Dexmedetomidine1.102
23eliprodil1.102
24Labetalol1.102
25Phenoxybenzamine1.102
26Platelet Activating Factor1.102
27Trazodone1.102
28Amlodipine0.691
29Losartan0.691
30amn0820.691
31Atenolol0.691
32Cyproheptadine0.691
33Dihydroergotamine0.691
34Guanabenz0.691
35Hydroxyzine0.691
36Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on0.691
37Loxapine0.691
38Metergoline0.691
39Pergolide0.691
40Phenylpropanolamine0.691

About ADRA1D as a Drug Target

ADRA1D (adrenoceptor alpha 1D) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 40 compounds with documented ADRA1D interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

ADRA1D inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.